286 related articles for article (PubMed ID: 22935556)
1. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A
Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068
[TBL] [Abstract][Full Text] [Related]
5. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
6. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
7. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
8. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
9. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
10. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
11. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
12. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
13. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
14. Use of hormonal protection for chemotherapy-induced gonadotoxicity.
Kim SS; Lee JR; Jee BC; Suh CS; Kim SH; Ting A; Petroff B
Clin Obstet Gynecol; 2010 Dec; 53(4):740-52. PubMed ID: 21048441
[TBL] [Abstract][Full Text] [Related]
15. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
Blumenfeld Z
Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
[TBL] [Abstract][Full Text] [Related]
16. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
17. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
Beck-Fruchter R; Weiss A; Shalev E
Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
[TBL] [Abstract][Full Text] [Related]
19. Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
Potolog-Nahari C; Fishman A; Cohen I
Gynecol Endocrinol; 2007 May; 23(5):290-4. PubMed ID: 17558688
[TBL] [Abstract][Full Text] [Related]
20. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.
Blumenfeld Z; Katz G; Evron A
Ann Oncol; 2014 Sep; 25(9):1719-1728. PubMed ID: 24651411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
